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Abstract 
Background: Chronic fatigue syndrome (CFS) is a prevalent and disabling condition among adolescent. The disease 
mechanisms are unknown. Previous studies have suggested elevated plasma levels of several cytokines, but a recent 
meta-analysis of 38 articles found that of 77 different cytokines measured in plasma, transforming growth factor beta 
(TGF-β) was the only one that was elevated in patients compared to controls in a sufficient number of articles. In the 
present study we therefore compared the plasma levels of the three TGF-β isoforms in adolescent CFS patients and 
healthy controls. In addition, the study explored associations between TGF-β levels, neuroendocrine markers, clinical 
markers and differentially expressed genes within the CFS group.
Methods: CFS patients aged 12–18 years (n = 120) were recruited nation-wide to a single referral center as part 
of the NorCAPITAL project (ClinicalTrials ID: NCT01040429). A broad case definition of CFS was applied, requiring 
3 months of unexplained, disabling chronic/relapsing fatigue of new onset, whereas no accompanying symptoms 
were necessary. Healthy controls (n = 68) were recruited from local schools. The three isoforms of TGF-β (TGF-β1, TGF-
β2, TGF-β3) were assayed using multiplex technology. Neuroendocrine markers encompassed plasma and urine levels 
of catecholamines and cortisol, as well as heart rate variability indices. Clinical markers consisted of questionnaire 
scores for symptoms of post-exertional malaise, inflammation, fatigue, depression and trait anxiety, as well as activity 
recordings. Whole blood gene expression was assessed by RNA sequencing in a subgroup of patients (n = 29) and 
controls (n = 18).
Results: Plasma levels of all three isoforms of TGF-β were equal in the CFS patients and the healthy controls. Sub-
grouping according to the Fukuda and Canada 2003 criteria of CFS did not reveal differential results. Within the CFS 
group, all isoforms of TGF-β were associated with plasma cortisol, urine norepinephrine and urine epinephrine, and 
this association pattern was related to fatigue score. Also, TGF-β3 was related to expression of the B cell annotated 
genes TNFRSF13C and CXCR5.
Conclusions: Plasma levels of all TGF-β isoforms were not altered in adolescent CFS. However, the TGF-β isoforms 
were associated with neuroendocrine markers, an association related to fatigue score. Furthermore, TGF-β3 might 
partly mediate an association between plasma cortisol and B cell gene expression.
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Background
Chronic fatigue syndrome (CFS) is a long-lasting and 
disabling condition characterized by disproportional 
fatigue after exertions, musculoskeletal pain, headaches, 
cognitive impairments, orthostatic intolerance and other 
symptoms [1, 2]. CFS is a major threat towards adoles-
cent health. The prevalence among teenagers is estimated 
at 0.1–1.0% [3, 4], and the condition may have detrimen-
tal effects on psychosocial and academic development 
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Disease mechanisms of CFS remain poorly understood. 
However, several studies indicate modest immunological 
alterations, such as enhancement of systemic inflamma-
tion [7–9] and attenuation of B cell function [10–12]. A 
recent study on whole blood gene expression in CFS cor-
roborated a general picture of increased innate immunity 
and decreased B cell differentiation and survival in CFS 
[13].
Despite these findings, studies of plasma cytokine levels 
have been inconclusive; findings include increased levels 
of interleukin (IL)-1 and tumor necrosis factor (TNF) 
[14], increased levels of IL-1α and IL-1β but normal lev-
els of TNF [15], and no differences between CFS patients 
and healthy controls [16, 17]. A recent review including 
meta-analysis of 38 articles studying all together 77 dif-
ferent cytokines, including interleukins, chemokines and 
growth factors, found evidence of elevated blood levels 
only of transforming growth factor beta (TGF-β) in CFS 
(63% of the studies), whereas other cytokines were not 
found to be consistently altered in any direction [18]. In 
a previous study from our laboratory [17], we found that 
the 27 plasma cytokines measured were identical in the 
CFS and the control group, without any tendency for dif-
ferences. This study using modern multiplex technique 
did not, however, include TGF-β, which here prompted 
us to investigate our population for this marker, in par-
ticular extending inclusion of all three different isoforms 
(denoted TGF-β1, TGF-β2 and TGF-β3).
TGF-β is excreted by macrophages and other immune 
cells. All isoforms are involved in a multitude of regula-
tory processes, including control of inflammation and 
specific immunity [19]. Notably, in some conditions, 
TGF-β promotes inflammatory responses combined with 
an inhibitory effect on several stages in B cell differentia-
tion and survival. Thus, TGF-β is a possible mediator of 
the subtly skewed immune responses observed in a pre-
vious CFS study [13]. Furthermore, TGF-β stimulates 
the generation of regulatory T cells [20], which has been 
shown to be increased in CFS by previous reports [21, 
22].
In addition to immune changes, CFS disease mecha-
nisms are characterized by neuroendocrine alterations 
including enhanced sympathetic and attenuated para-
sympathetic cardiovascular nervous activity [23–26] 
and attenuation of the hypothalamus–pituitary–adrenal 
(HPA) axis [27–29]. These phenomena might be caus-
ally related, as suggested in the “sustained arousal” model 
of CFS [30]. For instance, sympathetic activity is shown 
to enhance TGF-β3 mRNA expression in macrophages 
[31]. Another study has demonstrated a relationship 
between HPA dynamics and plasma levels of TGF-β1 
[32]. Recently, whole blood gene expression of immune 
annotated genes in CFS was demonstrated to be strongly 
associated with neuroendocrine markers of altered HPA-
axis and autonomic nervous activity [13]. Thus, a possi-
ble relationship between neuroendocrine alterations and 
TGF-β levels in CFS deserves further attention.
Symptoms that might suggest immune activation, 
such as chills, sore throat and tender lymphatic nodes, 
are common complaints among CFS sufferers [1, 33]. A 
previous study revealed no associations between plasma 
cytokine levels and symptom scores [17]. Still, a rela-
tionship between differential gene expression and symp-
toms of post-exertional malaise, which is considered a 
hallmark of the CFS phenotype, has been observed [13]. 
This finding warrants further exploration of associations 
between clinical symptoms and immune markers, includ-
ing TGF-β.
In general, the scientific investigation of adolescent 
CFS suffers several shortcomings as compared to adult 
CFS. For instance, to the best of our knowledge, no other 
studies have specifically addressed circulating TGF-β 
expression in adolescent CFS patients. Nevertheless, 
adolescent studies might benefit from low prevalence of 
comorbidity as well as a limited possibility of confound-
ing effects from aging processes.
Taken together, the main aim of the present study was 
to compare plasma levels of TGF-β isoforms in adoles-
cent CFS patients and healthy controls. We hypothe-
sized increased levels among the CFS patients based on 
the previous meta-analysis [18]. In addition, the present 
study had two exploratory aims: (a) To explore asso-
ciations between TGF-β levels, neuroendocrine markers 
and differentially expressed genes in the CFS group, and 




This study is part of the NorCAPITAL-project (The 
Norwegian Study of Chronic Fatigue Syndrome in Ado-
lescents: Pathophysiology and Intervention Trial; Clini-
calTrials ID: NCT01040429). Details of the recruitment 
procedure and inclusion/exclusion criteria are described 
elsewhere [34]. Briefly, all hospital pediatric departments 
in Norway (n  =  20), as well as primary care pediatri-
cians and general practitioners, were invited to refer CFS 
patients aged 12–18  years consecutively to our study 
center. A standard form required the referral unit to con-
firm the result of clinical investigations considered com-
pulsory to diagnose pediatric CFS according to national 
Norwegian recommendations (pediatric specialist assess-
ment, comprehensive hematology and biochemistry 
analyses, chest X-ray, abdominal ultrasound, and brain 
MRI). Also, the referring units were required to confirm 
that the patient (a) was unable to follow normal school 
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routines due to fatigue; (b) was not permanently bedrid-
den; (c) did not have any concurrent medical or psychi-
atric disorder that might explain the fatigue; (d) did not 
experience any concurrent demanding life event (such as 
parents’ divorce) that might explain the fatigue; (e) did 
not use pharmaceuticals (including hormone contracep-
tives) regularly. Patients considered eligible to this study 
were summoned to a clinical encounter at our study 
center after which a final decision on inclusion was made. 
The CFS group comprised 120 patients.
In agreement with clinical guidelines [2] and previous 
studies from our group [24–26], we applied a ‘broad’ case 
definition of CFS, requiring 3  months of unexplained, 
disabling chronic/relapsing fatigue of new onset. We did 
not require that patients meet any other accompany-
ing symptom criteria. Subgrouping of the participants 
according to the Fukuda case definition [35] and Canada 
2003 case definition [33] was performed post hoc, based 
on questionnaire results (cf. below).
Healthy controls
A group of healthy controls (n =  68) with a compara-
ble distribution of gender and age were recruited from 
local schools. Controls were not matched to cases on any 
variable. No chronic disease and no regular use of phar-
maceuticals (including hormone contraceptives) were 
allowed.
Study design and ethics
A 1-day in-hospital assessment included clinical exami-
nation and blood sampling and always commenced 
between 7.30 and 9.30 a.m. All participants were 
instructed to fast overnight and abstain from tobacco 
products and caffeine for at least 48  h. The partici-
pants were instructed to apply an ointment contain-
ing the local anesthetic lidocaine  (Emla®) on the skin 
in the antecubital area 1  h in advance. After at least 
5  min supine rest in calm surroundings, blood sam-
ples were obtained in a fixed sequence from antecubital 
venous puncture. A questionnaire was completed after 
the clinical encounter and returned in a pre-stamped 
envelope.
Data were collected in the period from March 2010 
until October 2012. The NorCAPITAL project has been 
approved by the Norwegian National Committee for 
Ethics in Medical Research (Reference ID: 2009/2541 
S-09354c). Written informed consent was obtained 
from all participants and from parents/next-of-kin if 
required. CFS patients were randomized to treatment 
with low-dose clonidine or placebo and followed for a 
total of 30  weeks; however, only baseline data are used 
in the present study. Details of the design are reported 
elsewhere [34].
TGF‑β isoforms: TGF‑β1, TGF‑β2 and TGF‑β3
The blood samples for TGF-β analyses were collected in 
4  ml EDTA tubes. The samples were placed on ice for 
approximately 30  min; thereafter, plasma was separated 
by centrifugation (2500g, 10  min, 4  °C) and frozen at 
− 80  °C until assayed. The samples were analyzed using 
Bio-Plex Human TGF-β 3-plex (Bio-Rad Laboratories 
Inc., Hercules, CA), containing the three isoforms of 
TGF-β: TGF-β1, TGF-β2 and TGF-β3. The assay was per-
formed using the Bio-Plex 200 system (Bio-Rad Labora-
tories Inc.) according to the manufactures’ instructions. 
All samples were obtained, treated stored and analysed in 
exactly in the same way, using the same personnel at each 
step, to exclude methodological variation since TGFβ 
is sensible for sample handling, including release from 
platelets.
Neuroendocrine markers
Blood samples for analyses of plasma norepinephrine 
and epinephrine were obtained in vacutainer tubes 
treated with ethylene glycol tetraacetic acid (EGTA)–
glutathione. The samples were placed on ice for approxi-
mately 30 min, and thereafter separated by centrifugation 
(2250×g, 15 min, 4 °C) and assayed by high-performance 
liquid chromatography (HPLC) with a reversed-phase 
column and glassy carbon electrochemical detector 
(Antec, Leyden Deacade II SCC, Zoeterwoude, The 
Netherlands) as described in detail elsewhere [29]. Blood 
samples for analyses of plasma cortisol were obtained in 
4 ml EDTA vacutainer tubes; plasma cortisol levels were 
determined by routine assays at the accredited laboratory 
at Oslo University Hospital, Norway. Morning spot urine 
samples for norepinephrine and epinephrine analyses 
were assayed with the same HPLC protocol as for plasma 
measurements, whereas morning spot urine free corti-
sol (non-conjugated cortisol) was assayed by solid phase 
competitive luminescence immunoassay (type  Immulite® 
2000, Siemens Healthcare Diagnostics, NY, USA). The 
urine levels of creatinine were analyzed using standard 
automatic analyzer techniques at the accredited labora-
tory at Oslo University Hospital, Norway.
Indices of heart rate variability (HRV) were obtained 
from ECG recordings of participants laying in a horizon-
tal position and connected to the Task Force Monitor 
(TFM) (Model 3040i, CNSystems Medizintechnik, Graz, 
Austria). Methodological details are provided elsewhere 
[36]. Power spectral analysis of HRV was automatically 
provided by the TFM, returning numerical values for low 
frequency (LF) power (0.05–0.17  Hz), high frequency 
(HF) power (0.17–0.4  Hz) and the LF/HF ratio. HF 
power is considered indicative of parasympathetic heart 
rate modulation, LF power reflects the combined effect 
of sympathetic and parasympathetic heart rate control, 
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whereas the LF/HF ratio is an index of sympathetic/para-
sympathetic balance.
Routine blood analyses
The serum concentration of C-reactive protein (CRP) 
was analyzed using a highly sensitive assay (Roche Diag-
nostics, Indianapolis, IN, USA), as described previously 
[34]. Hematology and biochemistry routine assays were 
performed at the accredited laboratory at Oslo University 
Hospital, Norway.
Whole blood gene expression
In a subgroup of 29 CFS patients and 18 healthy con-
trols, RNA was extracted from whole blood as described 
in details elsewhere [13]. RNA samples with RNA integ-
rity number value  ≥  7 were used for gene expression 
characterization by RNA sequencing (RNA-Seq) (Run 
by the Genomics Core Facilities at the Oslo University 
Hospital Radiumhospitalet). RNA reads were mapped 
to the human genome version GRCh38.p2 by STAR [37]. 
Gene expression abundance was quantified as reads 
mapped per exon by the Subread package [38]. Differen-
tially expressed genes (DEG) between CFS patients and 
controls were identified using DESeq2 package [39]. In 
order to correct for possible confounding background 
factors, age groups as scaling factor and gender input 
were included in the design model of DESeq2. Functional 
annotation of genes obtained from DESeq2 was done by 
uploading all DEGs into HumanMine [40].
Clinical markers
A CFS symptom inventory for adolescents assesses the 
frequency of 24 common symptoms during the preced-
ing month, as has been described elsewhere [34]. Briefly, 
each symptom is rated on a 5-point Likert scale, ranging 
from ‘never/rarely present’ to ‘present all the time’. The 
inventory includes the accompanying symptom of the 
Fukuda and Canada 2003 case definitions, facilitating 
post hoc subgrouping of CFS patients (Additional file 1). 
A composite score reflecting inflammatory symptoms 
was generated by taking the arithmetic mean across three 
single items (fever/chills, sore throat, and tender lym-
phatic nodes) and a composite score reflecting symptoms 
of post-exertional malaise was generated by taking the 
arithmetic mean across two single items (post-exertional 
fatigue and non-refreshing sleep). For both variables, 
the total range is from 0 to 5; higher scores imply more 
severe symptom burden.
The Chalder Fatigue Questionnaire (CFQ) total sum 
score is applied in the present study [41]; total range is 
from 0 to 33, where higher scores imply more severe 
fatigue. The mood and feelings questionnaire (MFQ) 
consists of 34 items, each scored on a 0–2 Likert scale; 
thus, the total sum score is from 0 to 68 [42]. The Spiel-
berger State-Trait Anxiety Inventory subscore reflecting 
trait anxiety is derived from the sum across 20 items; 
total range is from 20 to 80 [43]. The activPAL accelerom-
eter device (PAL Technologies Ltd, Glasgow, Scotland) 
was used for monitoring of daily physical activity during 
seven consecutive days [44], as described elsewhere [34].
Statistical analyses
All statistical analyses were carried out in SPSS (SPSS 
Inc., Chicago, Illinois, USA). A total of 9 individuals (6 
CFS patients, 3 healthy controls) had missing data for 
TGF-β analyses. As the CFS patients were included in a 
randomised controlled trial, individual data from follow-
up consultations (when available) were used for imputa-
tion of missing data at baseline. The remaining missing 
data (3 CFS patients, 3 healthy controls) were imputed 
using the mean values within each group. Missing data in 
other variables were not imputed.
Patients with CFS were compared with healthy controls 
by applying independent sample t tests, Mann–Whitney 
tests, Pearson Chi Square tests, or Fisher exact tests as 
appropriate. CFS patients adhering to the Fukuda crite-
ria and the Canada 2003-criteria were compared to the 
healthy controls in the same way. Associations between 
TGF-β and immune markers, neuroendocrine markers, 
single gene transcriptional counts and clinical markers 
within each group (CFS patients and healthy controls, 
respectively) were performed using correlation and lin-
ear regression analyses. A p < 0.05 was regarded as sta-
tistically significant. The correlation and linear regression 
analyses involved a multitude of statistical tests; however, 
as all these tests were considered exploratory, the p val-
ues were not adjusted.
Results
Demographic data
The 120 CFS patients fulfilling the inclusion criteria in 
the NorCAPITAL trial were included as the CFS patients 
group and 68 healthy individuals were included as con-
trol group [34]. The whole blood gene expression analy-
sis (RNA-seq) was carried out in a random subgroup of 
29 CFS patients and 18 healthy controls [13]. Gender, age 
and body mass index were equally distributed in the two 
groups (Table 1). In the CFS group, 98% were of Scandina-
vian ethnicity; 73% adhered to the Fukuda case definition 
and 38% to the Canada 2003-definition. With the exception 
of 1 patient, all belonging to the Canada 2003 subgroup 
also belonged to the Fukuda subgroup. A total of 2 CFS 
patients were on thyroid hormone supplement therapy, 1 
used melatonin and 1 used bronchodilators occasionally; 
no other pharmaceuticals were used. No CFS patients and 
3 healthy controls reported occasional use of illicit drugs; 
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78% in both groups reported no consume of alcoholic bev-
erages. CFS patient had higher levels of serum CRP, plasma 
norepinephrine and plasma epinephrine, and lower levels 
of heart rate variability (HRV) LF-power and urine cortisol-
to-creatinine ratio (Table 1). Also, CFS patients scored sig-
nificantly poorer on all clinical markers (Table 1).
Table 1 Demographic characteristics
P values in italics indicate statistical significance
n/a not applicable, SD standard deviation, IQR interquartile range, LF low-frequency power of heart rate variability, HF high-frequency power of heart rate variability
a Cf. Ref. [35]
b Cf. Ref. [33]
c Statistical comparison across CFS group and HC group are based upon Independent sample t test, Mann–Whitney test or Fisher exact test as appropriate




88 73 46 68 0.563
 Age (years)
Mean, SD
15.4 1.6 15.1 1.6 0.179
 Body mass index (kg/m2)
Mean, SD
21.5 4.2 20.6 3.7 0.119
 Disease duration (months)
Median, range
18 4–104 n/a
 Adheres to the Fukuda criteria of  CFSa
Number, %
88 73 n/a
 Adheres to the Canada 2003-criteria of  CFSb
Number, %
46 38 n/a
Immune, autonomic and neuroendocrine markers
 Serum C-reactive protein (mg/l)
Median, IQR
0.43 0.96 0.35 0.46 0.049
 Heart rate variability, LF power (abs)
Median, IQR
481 772 682 1514 0.015
 Heart rate variability, HF power (abs)
Median, IQR
788 1835 1058 1837 0.070
 Heart rate variability, LF/HF-ratio
Median, IQR
0.69 0.64 0.74 0.38 0.792
 Plasma norepinephrine (pmol/l)
Mean, SD
1991 783 1483 422 < 0.001
 Plasma epinephrine (pmol/l)
Median, IQR
308 131 265 95 0.001
 Plasma cortisol (nmol/l)
Mean, SD
367 143 351 150 0.460
 Urine norepinephrine/creatinine ratio (nmol/mmol)
Median, IQR
12.3 5.8 10.8 5.8 0.102
 Urine epinephrine/creatinine ratio (nmol/mmol)
Median, IQR
1.3 1.2 1.5 1.0 0.649
 Urine cortisol/creatinine ratio (nmol/mmol)
Median, IQR
3.4 3.1 5.3 6.0 0.001
Clinical makers
 Symptoms of post-exertional malaise (total score)
Mean, SD
4.0 1.0 1.4 0.5 < 0.001
 Inflammatory symptoms (total score)
Mean, SD
2.1 0.9 1.3 0.5 < 0.001
 Chalder Fatigue Questionnaire (total score)
Mean, SD
19.3 6.1 8.7 4.6 < 0.001
 Moods and Feelings Questionnaire (total score)
Mean, SD
17.4 10.0 6.4 7.8 < 0.001
 Spielberger state-trait anxiety questionnaire (trait subscore)
Mean, SD
43.2 8.9 32.3 7.2 < 0.001
 Steps per day (number)
Mean, SD
4662 2386 10,293 3716 < 0.001
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Transforming growth factor‑β (TGF‑β)
Plasma levels of all three isoforms of TGF-β (TGF-β1, 
TGF-β2 and TGF-β3) were equal in CFS patients and 
healthy controls (Table  2, Additional file  2: Table S1). 
Subgroup analyses revealed no differential results, nei-
ther for the Fukuda case definition nor for the Canada 
2003-definition. Within the CFS group, TGF-β was not 
associated with clinical markers (Additional file 3: Table 
S2). Also, whole blood transcriptional counts from the 
TGFB1 gene in the subgroup subjected to RNA-seq were 
equal among CFS patients and healthy controls (1184 vs 
1208, p = 0.712).
TGF‑β, neuroendocrine markers and fatigue score
Plasma levels of TFG-β were associated with neuroen-
docrine markers, in particular plasma cortisol as well as 
plasma and urine catecholamines. Multiple linear regres-
sion analyses revealed that these associations differed in 
CFS patients and healthy controls (Fig. 1), despite similar 
levels of TFG-β in the two groups. In the CFS patients, 
all TGF-β isoforms were significantly and independently 
associated with plasma cortisol, urine norepinephrine-
to-creatinine ratio and urine epinephrine-to-creatinine 
ratio, whereas no significant associations to these mark-
ers were observed among healthy control. This differen-
tial association pattern was related to symptom severity 
(Table  3). When divided according to fatigue severity 
(Chalder Fatigue Questionnaire), CFS patients with the 
highest fatigue score (≥ 20) displayed the strongest asso-
ciations between TGF-β and neuroendocrine markers, 
whereas CFS patients with the lowest fatigue score (< 20) 
had a pattern of associations that was more similar to the 
one observed in healthy controls.
Immune gene transcripts
Only a few differentially expressed immune gene tran-
scripts were associated with TGF-β (Additional file  4: 
Table S3). However, there was a negative association, 
most evident for the TGF-β3 isoform, to the B cell anno-
tated genes TNFRSF13C and CXCR5, which are both 
downregulated in CFS. Multiple linear regression analy-
ses were consistent with a model in which TGF-β3 partly 
mediated the effect of plasma cortisol on the expression 
of these genes (Fig. 2).
Discussion
There were three main finding of this study: (1) plasma 
levels of the three TGF-β isoforms did not differ in ado-
lescent CFS patients as compared to healthy controls. 
(2) Within the CFS group, plasma levels of all TGF-β 
isoforms were associated with plasma levels of cortisol 
and urine levels of catecholamines. In addition, TGF-β3 
might partly mediate the association between plasma 
cortisol and downregulation of some B cell annotated 
genes. (3) Plasma level of TGF-β was not directly related 
to CFS symptoms; however, the association of neuroen-
docrine mediators with TGF-β were related to fatigue 
score.
The lack of differences between CFS patients and 
healthy controls corroborate previous findings of nor-
mal plasma cytokine levels in CFS [17, 18]. Of note, sub-
grouping according to the Fukuda criteria or the Canada 
2003-criteria did not reveal differential results. This is 
also in line with previous observations [17, 45]. While 
immunological alterations have been reported in many 
CFS studies, there seems to be no consistent pattern of 
plasma cytokine disturbances, calling for more specific 
investigations of immune mechanisms in different bodily 
compartments.
Previous studies have demonstrated a complex and 
possible bi-directional relationship between TGF-β 
levels and HPA axis activity [32, 46]. Similarly, TGF-β 
secretion has been associated with sympathetic nervous 
activity [47, 48] as well as plasma catecholamines [49]. 
Interestingly, in the present study, linear associations 
between TGF-β levels and neuroendocrine markers 
Table 2 TGF-β isoforms across CFS patients (including Fukuda and Canada 2003-subgroups) and healthy controls
TGF transforming growth factor beta, SD standard deviation, IQR interquartile range
a Compared with healthy controls. Statistical comparisons across groups are based upon Independent sample t test or Mann–Whitney test as appropriate
CFS patients 
(n = 120)
p  valuea Healthy controls 
(n = 68)
CFS, Fukuda sub‑
group (n = 88)






4927 5157 0.482 5692 6350 4944 4276 0.599 4880 6247 0.831
Plasma TGF-β2 (pg/ml)
Mean, SD
758 262 0.928 754 278 712 246 0.809 780 252 0.621
Plasma TGF-β3 (pg/ml)
Median, IQR
230 227 0.901 251 250 230 208 0.990 243 254 0.760
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were found among CFS patients only. Moreover, within 
the CFS group, this picture was remarkably consistent 
across all TGF-β isoforms (Fig.  1), and related to the 
clinical symptom of fatigue (Table  3). Taken together, 
the results of the present study seem to suggest that 
underlying disease mechanisms of CFS are more related 
to altered immunological control than to altered levels 
of immune markers per se. Similar observations have 
been reported in a study of neuroendocrine regula-
tory systems [29], and are also in line with findings of 
a relationship between HPA axis dynamics and clinical 
symptoms [50, 51].
On a more general level, the findings of the present 
study seem to comply with the “sustained arousal” model 
of CFS [30]. In this model, a maladaptive stress response 
is considered a central pathophysiological element, elicit-
ing autonomic and neuroendocrine alterations which in 
turn are responsible for subtle immunological alterations. 
Thus, an association between neuroendocrine markers 
and immune markers is predicted from this model, in line 
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Fig. 1 Multiple linear regression models exploring associations between neuroendocrine markers and isoforms of TGF-β in CFS patients (a) and 
healthy controls (b). Significant associations are indicated with a continuous arrow, whereas associations close to the level of significance are indi-
cated with a dotted arrow. P-NorEpi plasma norepinephrine, P-Epi plasma epinephrine, P-Cortisol plasma cortisol, U-NorEpi urine norepinephrine-to-
creatinine ratio, U-Epi urine epinephrine:creatinine ratio, U-Cortisol urine cortisol:creatinine ratio, P-TGF plasma transforming growth factor
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with the reported findings. It should be noted, though, 
that the cross-sectional design of the present study does 
not allow inference of causality. Further research should 
aim at uncover underlying mechanisms; one promising 
field of study might be epigenetic alterations of the gluco-
corticoid receptor gene [52].
The findings of a possible relationship between TGF-
β3 and B cell annotated gene transcripts should be inter-
preted with great caution due to the limited number of 
CFS patients undergoing RNA-seq (n  =  29). However, 
the findings were rather specific for the TGF-β3 isoform, 
reducing the risk of a type 1-error. Besides, it is not bio-
logically implausible that TGF-β3 might act as a media-
tor of a cortisol effect on B cell gene expression. This 
observation should be explored further in mechanistic 
studies of immune cell function, in particular since the 
Epstein–Barr virus (EBV) is known to be a common pre-
cipitating factor in CFS [1]. Infection of EBV in human 
is persistent and tightly associated with B cell differentia-
tion pathways. EBV establishes its long-term latency in 
memory B cells where its ability of switching from latent 
to lytic form of infection is related to the differentiation 
state of the cell [53]. Interestingly, it has been shown that 
TGF-β can induce EBV reactivation in vitro [54], and that 
expression of some of EBV promoters is activated in B 
cells upon TGF-β binding to TGF receptors [55].
In general, however, our data indicate that all three iso-
forms of TFG-β behave similar and that the previous data 
Table 3 Multiple linear regression models for neuroendocrine markers and plasma TGF-β in CFS patients with high 
fatigue score (≥ 20), CFS patients with low fatigue score (< 20), and healthy controls
P values in italics indicate statistical significance
B regression coefficient (unstandardized), CI confidence interval, R2 explained variance of the dependent variable
a The ln-transformed variable was used (better approximation to a normal distribution)
b Fatigue score was missing from 4 CFS patients
CFS patients, high fatigue score 
(n = 62)b
CFS patients, low fatigue score 
(n = 54)b
Healthy controls (n = 68)
Model 1
 Dependent variable
  Plasma TGF-β1a B (CI) p value R2 B (CI) p value R2 B (CI) p value R2
 Independent variables
  Plasma cortisol 1.9 × 10−3 (0.18 to 
3.5 × 10−3)
0.031 0.17 0.26 × 10−3 (− 1.6 to 2.1 
x  10−3)
0.780 0.12 − 0.19 × 10−3 (− 1.9 to 
1.5 × 10−3)
0.825 0.07
  Urine norepineph-
rine/creatinine 
 ratioa
0.99 (0.20 to 1.8) 0.015 0.60 (0.01 to 1.2) 0.048 0.62 (− 0.06 to 1.3) 0.071
  Urine epinephrine/
creatinine  ratioa
− 0.65 (− 0.65 to 
− 0.06)
0.031 − 0.39 (− 0.77 to 
− 0.02)
0.042 0.004 (− 0.47 to 0.48) 0.987
Model 2
 Dependent variable
  Plasma TGF-β2 B (CI) p value R2 B (CI) p value R2 B (CI) p value R2
 Independent variables
  Plasma cortisol 0.64 (0.22 to 1.1) 0.003 0.22 0.07 (− 0.49 to 0.62) 0.814 0.12 − 0.01 (− 0.49 to 0.46) 0.950 0.05
  Urine norepineph-
rine/creatinine 
 ratioa
248 (50 to 447) 0.015 133 (− 44 to 311) 0.136 160 (− 28 to 349) 0.094
  Urine epinephrine/
creatinine  ratioa
− 161 (− 308 to − 14) 0.032 − 132 (− 246 to − 18) 0.024 − 16 (− 148 to 115) 0.806
Model 3
 Dependent variable
  Plasma TGF-β3a B (CI) p value R2 B (CI) p value R2 B (CI) p value R2
 Independent variables
  Plasma cortisol 2.0 × 10−3 (0.60 to 
3.4 × 10−3)
0.006 0.20 0.17 × 10−3 (− 1.6 to 
1.9 × 10−3)
0.851 0.11 − 0.4 × 10−3 (− 1.8 to 
0.99 × 10−3)
0.565 0.07
  Urine norepineph-
rine/creatinine 
 ratioa
0.78 (0.12 to 1.4) 0.022 0.40 (− 0.17 to 1.0) 0.164 0.50 (− 0.06 to 1.1) 0.076
  Urine epinephrine/
creatinine  ratioa
− 0.52 (− 1.0 to − 0.03) 0.038 − 0.41 (− 0.77 to 
− 0.05)
0.027 − 0.01 (− 0.40 to 0.38) 0.964
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published with TFG-β, using isoform 1, is transferable to 
the other two isoform. To the best of our knowledge, this 
is the first study comparing the three TGF-isotypes. Of 
even more importance is that the only cytokine from the 
meta-analysis of 38 articles and 77 cytokines [18] shown 
to be a possible mediator discriminating CFS patients 
from controls, namely the TGF-β, fail to be shown in the 
present study, leaving no systemic cytokines left for this 
purpose.
Limitations of the present study encompass the wide 
inclusion criteria which might have obscured results 
pertaining to a subgroup. However, adjusting for adher-
ence to the Fukuda and Canada 2003 case definitions did 
not alter the cross-sectional comparison. Also, the fact 
that our inclusion criteria are not identical to common 
international standards might reduce generalizability. As 
this study only included adolescents, we do not know to 
what extent the results apply to adult CFS patients. The 
number of patients that underwent whole blood gene 
expression by RNA-seq was rather low, increasing the 
risk of type II-errors. Although blood samples for cortisol 
analyses were obtained at a standardized time point, we 
cannot rule out that sleep problems and disturbances of 
the diurnal rhythm in the CFS group might have con-
founded the results. The composite scores reflecting 
inflammatory symptoms and symptoms of postexertional 
malaise has not been formally validated, and it is possible 
that a relationship between TGF-β levels and symptoms 
might have been discovered using inventories with higher 
sensitivity. Furthermore, we have not assessed responses 
to exercise and other stimuli. Normal levels at rest do not 
rule out abnormal response patterns. Finally, the nature 
of a cross-sectional study does not allow any causal infer-
ences to be made.
Conclusions
The main finding of this study is that plasma levels of 
the three TGF-β isoforms were equal in a large group 
of adolescent CFS patients compared to healthy con-
trols. In addition, within the CFS group, plasma level of 
all TGF-β isoforms were associated with plasma levels 








































Fig. 2 Multiple linear regression models in a subgroup of CFS patients (n = 29). a Previous established associations between blood monocyte 
count and plasma cortisol, and the expression in whole blood of the genes TNFRSF13C (tumor necrosis factor receptor superfamily member 13C) 
and CXCR5 (C-X-C motif chemokine receptor 5) (Nguyen et al. [13]). b The associations after introducing TGF-β3 as a mediating variable in the 
regression model. Significant associations are indicated with a continuous arrow, associations close to the level of significance are indicated with a 
dotted arrow. B-Mono blood monocyte count, P-Cortisol plasma cortisol, P-TGF plasma transforming growth factor
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associations were related to fatigue score. Finally TGF-β3 
might partly mediate an association between plasma cor-
tisol and downregulation of some B cell annotated genes. 
These latter observations should be addressed in further 
studies aiming at unraveling the complex causal inter-
plays between neuroendocrine signaling, subtle immune 
alterations and clinical symptoms in CFS.
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